NEWS & MEDIA

Image Alt Text

Neovacs Announces Positive Data Review from Last IDSMB Review Prior to Final Results of Phase IIb Clinical Trial of IFNalpha Kinoid in Lupus

 Final Trial Results Expected in June 2018

 Paris and Boston, February 13th 2018, 07:00 am CET – Neovacs (Euronext Growth: ALNEV), a leader in active immunotherapy for the treatment of autoimmune diseases, today announces that it has received a positive data review from the Independent Data and Safety Monitoring Board (IDSMB) related to the ongoing Phase IIb clinical trial of IFNalpha Kinoid in lupus.  This was the last IDSMB data review prior to the final results from this trial.

 

 

Read More

NEOVACS STRENGTHENS INTELLECTUAL PROPERTY POSITION IN EUROPE...

Newly issued patent covers IFNalpha Kinoid and its application in all diseases related to an overproduction of...

NEOVACS PROVIDES CORPORATE UPDATE AND REPORTS FULL-YEAR 2017...

Paris, March 30, 2018, 7:30 am CEST  – NEOVACS (Euronext Growth Paris: ALNEV), a leader in active...

NEOVACS’ ANNOUNCES THE SUCCESS OF ITS GENERAL MEETING OF...

Paris and Boston, March 12, 2018 – 6.00 pm CET – Neovacs (Euronext Growth Paris: ALNEV), a leader in...

Neovacs Announces Positive Data Review from Last IDSMB Review...

Final Trial Results Expected in June 2018   Paris and Boston, February 13th 2018, 07:00 am CET – Neovacs...

NEOVACS STRENGTHENED ITS INTELLECTUAL PROPERTY IN RUSSIA...

 This patent covers IFNalpha kinoid and its application in all diseases related to an overproduction of...